Overview
SPRO market data
Price History
SPRO price chart · 3M
- O
- 1.22
- H
- 1.22
- L
- 1.18
- C
- 1.22
- Vol
- 31,202.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.22
- Previous Close
- $1.21
- Day High
- $1.22
- Day Low
- $1.18
- 52 Week High
- $3.07
- 52 Week Low
- $1.09
- 7 Day Return
- +0.00%
- 30 Day Return
- +1.67%
- 90 Day Return
- -56.91%
- 1 Year Return
- -51.98%
- Daily Notional Volume
- $37.9K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 4.73 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.49 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 24.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.08 – $3.08 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $72.1M · P/B 2.22 · P/S 1.18.
Company News
8-K filing — Spero Therapeutics, Inc. (SPRO)SEC EDGAR · Aug 12, 2026, 8:09 PM
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoYBenzinga · Aug 12, 2026, 8:01 PM
Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.Benzinga · Jul 14, 2026, 5:12 PM
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyGlobenewswire Inc · Jul 14, 2026, 11:00 AM
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare RoyaltyBenzinga · Jul 14, 2026, 10:11 AM
Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-ChinaBenzinga · Jul 14, 2026, 10:09 AM
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsBenzinga · Jun 17, 2026, 6:15 PM
GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract InfectionsBenzinga · Jun 17, 2026, 3:30 PM